ZED-1227

DB19208InvestigationalSmall molecule

ZED-1227 is under investigation in clinical trial NCT05305599 (Different Doses of ZED1227 vs. Placebo in NAFLD).

Formula / weight: C₂₆H₃₆N₆O₆ · 528.61 g/mol (avg)
Also known as: (2e,6s)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1h-imidazol-5-yl)carbonyl)amino)-7-oxo-2-heptenoic acid methyl ester · 2-heptenoic acid, 7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-1,2-dihydro-2-oxo-3-pyridinyl)amino)-6-(((1-methyl-1h-imidazol-5-yl)carbonyl)amino)-7-oxo-, methyl ester, (2e,6s)- · Methyl (e,6s)-7-((1-(2-(2-ethylbutylamino)-2-oxo-ethyl)-2-oxo-3-pyridyl)amino)-6-((3-methylimidazole-4-carbonyl)amino)-7-oxo-hept-2-enoate
Code names: TAK-227 · ZED-1227

Resolves to

Compound

Structure

InChIKeyVHGWUSABWIEXKQ-BEBFYNPSSA-NSMILESCCC(CC)CNC(=O)CN1C=CC=C(NC(=O)[C@H](CC\C=C\C(=O)OC)NC(=O)C2=CN=CN2C)C1=O

Targets

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with ZED-1227, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.